CytomX Therapeutics (NASDAQ:CTMX) Stock Rating Upgraded by StockNews.com

CytomX Therapeutics (NASDAQ:CTMX) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a note issued to investors on Monday.

Several other research analysts have also recently issued reports on the company. HC Wainwright reiterated a “neutral” rating on shares of CytomX Therapeutics in a research report on Friday. Wedbush restated an “outperform” rating and issued a $5.00 price target on shares of CytomX Therapeutics in a research report on Friday. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $5.02.

CytomX Therapeutics Stock Up 0.7 %

Shares of NASDAQ CTMX traded up $0.00 during mid-day trading on Monday, hitting $0.67. 4,568,857 shares of the company were exchanged, compared to its average volume of 2,619,562. The stock has a 50 day simple moving average of $0.84 and a 200-day simple moving average of $1.01. CytomX Therapeutics has a 1-year low of $0.60 and a 1-year high of $5.85. The firm has a market cap of $52.41 million, a price-to-earnings ratio of 3.94 and a beta of 1.05.

CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings data on Thursday, March 6th. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.45. The firm had revenue of $38.09 million during the quarter, compared to analysts’ expectations of $13.53 million. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. Analysts anticipate that CytomX Therapeutics will post -0.05 earnings per share for the current fiscal year.

Institutional Trading of CytomX Therapeutics

Large investors have recently made changes to their positions in the stock. Miller Financial Services LLC acquired a new stake in shares of CytomX Therapeutics during the fourth quarter valued at $26,000. Traphagen Investment Advisors LLC acquired a new stake in shares of CytomX Therapeutics during the fourth quarter valued at $31,000. Algert Global LLC acquired a new stake in shares of CytomX Therapeutics during the fourth quarter valued at $35,000. US Bancorp DE acquired a new stake in shares of CytomX Therapeutics during the third quarter valued at $40,000. Finally, Velan Capital Investment Management LP acquired a new stake in shares of CytomX Therapeutics during the fourth quarter valued at $36,000. Institutional investors and hedge funds own 67.77% of the company’s stock.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.